

PROVINCIAL FUNDING SUMMARY

Bendamustine hydrochloride (Treanda) for Chronic Lymphocytic Leukemia (relapsed/refractory)

pERC Recommendation: Does not recommend
For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 14, 2012

This information is current as of February 23, 2016. The use of this document is directed by [pCODR's Terms of Use](#).

Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Feb 1, 2013	Relapsed or refractory chronic lymphocytic leukemia; advanced stage symptomatic disease requiring therapy; relapsed or refractory disease no longer controlled by BCCA standard treatment including fludarabine +/- rituximab, alkylator-based therapy (cyclophosphamide, vincristine and prednisone) and alemtuzumab. NOTE: A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment.
AB	Funded	Mar 1, 2013	Bendamustine in combination with rituximab for relapsed/refractory patients with indolent NHL or mantle cell lymphoma. Note that our tumor group views indolent NHL to include but not be limited to: small lymphocytic lymphoma/CLL and others.
SK	Not funded		
MB	Not funded		
ON	Not funded		
NS	Not funded		
NB	Not funded		
NL	Not funded		
PEI	Not funded		